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Background: There is no known receptor for the nucleotide AMP.
Results: AMP directly activates the adenosine A1 receptor (A1R) but not the adenosine A2B receptor.
Conclusion: A1R is a receptor for adenosine and AMP.
Significance:The diverse physiological effects of AMP could be due to direct, ectonucleotidase-independent activation of A1R.
Numerous receptors forATP,ADP, andadenosine exist; how-
ever, it is currently unknown whether a receptor for the related
nucleotide adenosine 5-monophosphate (AMP) exists. Using a
novel cell-based assay to visualize adenosine receptor activation
in real time, we found that AMP and a non-hydrolyzable AMP
analog (deoxyadenosine 5-monophosphonate, ACP) directly
activated the adenosine A1 receptor (A1R). In contrast, AMP
only activated the adenosine A2B receptor (A2BR) after hydroly-
sis to adenosine by ecto-5-nucleotidase (NT5E, CD73) or pros-
tatic acid phosphatase (PAP, ACPP). Adenosine and AMP were
equipotent human A1R agonists in our real-time assay and in a
cAMP accumulation assay. ACP also depressed cAMP levels in
mouse cortical neurons through activation of endogenous A1R.
Non-selective purinergic receptor antagonists (pyridoxalphos-
phate-6-azophenyl-2,4-disulfonic acid and suramin) did not
block adenosine- or AMP-evoked activation. Moreover, muta-
tionofHis-251 in thehumanA1R ligandbindingpocket reduced
AMP potency without affecting adenosine potency. In contrast,
mutation of a different binding pocket residue (His-278) elimi-
nated responses to AMP and to adenosine. Taken together, our
study indicates that the physiologically relevant nucleotide
AMP is a full agonist of A1R. In addition, our study suggests that
some of the physiological effects of AMPmay be direct, and not
indirect through ectonucleotidases that hydrolyze this nucleo-
tide to adenosine.
Adenosine and adenine nucleotides regulate diverse physio-
logical processes (1, 2). Adenosine activates four distinct G pro-
tein-coupled receptors, the so-called P1 purinergic receptors:
adenosine A1 receptor (A1R,2 ADORA1), adenosine A2A recep-
tor (A2AR, ADORA2A), adenosine A2B receptor (A2BR,
ADORA2B), and adenosine A3 receptor (A3R, ADORA3). A1R
and A3R are Gi/o-coupled and inhibit adenylate cyclase when
activated, whereas A2AR and A2BR are Gs-coupled and stimu-
late adenylate cyclase.
Although mammals have numerous P2 purinergic receptors
for ATP and ADP, no receptor for their hydrolysis product
(AMP) has been definitively identified. GPR80/GPR99 was
originally classified as an adenosine and AMP receptor (3);
however, this finding has now been discounted (4, 5). AMP has
diverse physiological effects, suggesting that a receptor for
AMP could exist (6–15).
Complicating studies with AMP is the fact that cells express
multiple enzymes that hydrolyze extracellular AMP to adeno-
sine, including ecto-5-nucleotidase (NT5E, CD73), prostatic
acid phosphatase (PAP, ACPP), and several alkaline phospha-
tases (16–19). Genetic deletion or pharmacological inhibition
of individual ectonucleotidases reduces, but does not always
eliminate, the physiological effects of AMP (6, 8, 11, 13, 20). In
addition, the most commonly used ectonucleotidase inhibitor
,-methylene-ADP (-met-ADP) inhibits NT5E, but it does
not inhibit PAP (11).
Many of the physiological effects of AMP are lost in A1R
knock-out mice or can be blocked with adenosine receptor
antagonists (6, 8, 11, 13–15), suggesting that adenosine is the
active ligand. However, given the challenges associated with
inhibiting all ectonucleotidases in complex tissues (20), direct
activation of adenosine receptors by AMP cannot be easily
ruled out.
Extracellular AMP originates from multiple endogenous
sources (16), and nucleotide release and hydrolysis can be rapid
(20, 21). Endogenous AMP could thus directly modulate
diverse adenosine receptor-dependent processes, including
cardiovascular disease, cancer, neurotransmission, and glio-
transmission (1, 2, 22–24).
To rigorously study direct and indirect effects of AMP on
adenosine receptors, we developed a novel cell-based assay uti-
lizing chimeric G proteins to visualize human (h)A1R and
hA2BR activation in real time and at single cell resolution. We
also used a non-hydrolyzableAMPanalog to rule out the effects
of AMP hydrolysis. Surprisingly, we found that AMP directly
activated hA1R, but not hA2BR, and activationwas independent
of hydrolysis to adenosine. Thus, our study indicates that A1R is
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a receptor for the naturally occurring nucleotideAMPaswell as
a receptor for adenosine.
EXPERIMENTAL PROCEDURES
Animal Care and Use—All procedures involving vertebrate
animals were approved by the Institutional Animal Care and
Use Committee.
Calcium Imaging—HEK293 cells were grown on polylysine-
coated glass bottom culture dishes (MatTek Corp., P35G-0-
10-C) in Dulbecco’s modified Eagle’s medium (DMEM) con-
taining 10% fetal bovine serum, 100 units/ml penicillin and 100
g/ml streptomycin. Cells were transfected with Lipo-
fectamine Plus (Invitrogen) in DMEM containing 1% fetal
bovine serum, which was replaced with fresh growth medium
after 4 h. The total amount of DNA per transfection was
adjusted to 1g by adding pcDNA3.1(). 100 ng of pCS-Venus
was included in each transfection to identify transfected cells.
Following transfection (24 h), cells were washed two times in
Hanks’ balanced salt solution assay buffer (Invitrogen catalogue
number 14025, supplemented with 9mMHEPES, 11mM D-glu-
cose, 0.1% fatty acid-free bovine serum albumin, pH 7.3), and
then loaded for 1 h at room temperature with 2 M Fura-2 AM
(Invitrogen, F-1221) and 0.02% Pluronic F-127 (Invitrogen,
P3000-MP) in assay buffer. Cells were washed three times with
assay buffer, incubated for 30 min at room temperature, and
imaged on a Nikon Eclipse Ti microscope.
A SutterDG-4 light source (excitation 340nm/380nm; emis-
sion 510 nm) andAndor Clara CCD camera were used to image
calcium responses. Assay buffer was refreshed immediately
prior to imaging. Antagonists were added in assay buffer 3 min
prior to imaging. Starting solution was aspirated, and agonist
solution was added after 40 s of baseline imaging.Wemanually
pipetted and aspirated solutions for all calcium imaging exper-
iments. Only cells that expressed visible Venus protein, did not
saturate the camera at a 40-ms exposure time, and had low
(0.6) baseline Fura-2 ratios were analyzed. 500-ms excitation
at 340 nm and 250-ms excitation at 380 nm were used for all
experiments.
Calcium responses were analyzed in two ways. To create
real-time response profiles, the Fura-2 fluorescence intensity
ratio (340 nm/380 nm) at each time point was averaged over all
transfected cells in each condition and then normalized relative
to the average baseline fluorescence ratio before agonist addi-
tion. Calcium responses were also quantified by calculating the
area under the curve (AUC) extending 1min from agonist addi-
tion, relative to the baseline fluorescence ratio, on a cell-by-cell
basis. AUC values were then averaged over all cells in each
condition. Calcium response profiles and AUC data are pre-
sented as mean  S.E. To create dose-response curves,
GraphPad Prism was used to fit a variable slope dose-response
equation to the average AUC values for each agonist concen-
tration. Detailed descriptions of materials and protocols can be
found in the supplemental Experimental Procedures.
RESULTS
Chimeric G Proteins Can Be Used to Visualize Adenosine
Receptor Activation in Real Time—Activation of Gi-coupled
A1R or Gs-coupled A2BR is typically quantified by measuring
ligand-evoked decreases or increases in intracellular cAMP,
respectively. However, these assays entail lysing cells at differ-
ent times after stimulation; hence these assays have limited
temporal resolution and no cellular resolution. In an effort to
develop a real-time readout of adenosine receptor activation,
we co-transfected HEK293 cells with vectors encoding hA1R
and Gq-i5 (Gqi), a chimeric G protein that couples Gi-coupled
receptors to phospholipase C (PLC) activation and calcium
mobilization (supplemental Fig. S1) (25). In parallel, we
co-transfected HEK293 cells with vectors encoding hA2BR and
chimeric Gq-s5 (Gqs) to couple hA2BR to PLC and calcium
mobilization (supplemental Fig. S1) (26). As controls, we found
that adenosine (1 mM) did not evoke calcium mobilization in
untransfected HEK293 cells or in cells expressing hA1R alone,
hA2BR alone, Gqi alone, or Gqs alone. However, a saturating
concentration of adenosine (1 mM) evoked rapid onset calcium
responses that slowly decayed in cells co-expressing hA1R 
Gqi or hA2BRGqs (Fig. 1,A andB), indicating that adenosine
receptor activation can be monitored in real time at cellular
resolution.
AMP Activates hA1R Independent of Ectonucleotidases,
whereas hA2BR Activation Is Ectonucleotidase-dependent—Be-
cause no AMP receptors have been definitively identified, we
next hypothesized that AMP would only mobilize calcium in
adenosine receptor-expressing cells after hydrolysis to adeno-
sine by PAP or NT5E ectonucleotidases (supplemental Fig. S1).
To test this hypothesis, we co-transfected cells with hA1R 
Gqi vectors along with the membrane-bound ectonucleoti-
dases PAP or NT5E. These ectonucleotidases were enzymati-
cally active when expressed in HEK293 cells (see supplemental
Experimental Procedures). To our initial surprise, 1 mM AMP
evoked calcium responses in hA1R  Gqi-expressing cells that
were indistinguishable in onset and magnitude from calcium
responses evoked by 1mMadenosine, and co-expression of PAP
orNT5E did notmodify AMP-evoked responses (Fig. 1A). Sim-
ilar results were observed in cells co-expressing mouse A1R 
Gqi (supplemental Fig. S2). These AMP-evoked calcium
responses were dependent on overexpressed A1R as AMP had
no effect in HEK293 cells when Gqi was expressed alone (Fig.
1A, supplemental Fig. S2). Rapid activation of A1R was not due
to contaminating levels of adenosine (adenosine was undetect-
able in our AMP stock solution based on high performance
liquid chromatography analysis). Instead, our data suggested
that a nucleotide (AMP) could directly activate the adenosine
A1 receptor.
In contrast, adenosine (Fig. 1B, gray) andAMP (Fig. 1B, blue)
evoked kinetically distinct calcium responses in hA2BR  Gqs
co-expressing HEK293 cells. Specifically, adenosine evoked a
rapid onset calcium response that peaked shortly after agonist
addition, whereasAMPelicited a gradual calcium response that
began 15 s after agonist addition. Co-expression of PAP or
NT5E significantly augmented the speed and magnitude of the
AMP response (Fig. 1B, green and purple), suggesting that these
enzymes accelerated the hydrolysis of AMP to adenosine.
Although HEK293 cells endogenously express hA2BR (3, 27),
AMP did not evoke calcium responses in cells expressing Gqs
alone (Fig. 1B, black). Taken together, these data suggest that
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AMP only activates hA2BR indirectly following hydrolysis to
adenosine.
To directly test whether AMP activates hA1R or hA2BR as a
result of ectonucleotidase activity, we repeated our experi-
ments in the presence of -met-ADP, a high potency (Ki  5
nM) NT5E inhibitor (28). We found that -met-ADP did not
inhibit adenosine- or AMP-evoked calcium responses in cells
co-expressing hA1R  Gqi (with or without overexpressed
ectonucleotidases) (compare Fig. 1Awith Fig. 1C), further sug-
gesting that AMP stimulates hA1R directly. In contrast, 10 M
-met-ADP completely inhibited the calcium response
caused by AMP in hA2BRGqs-expressing cells (Fig. 1D, blue)
but did not inhibit the adenosine-evoked calcium response (Fig.
1D, gray). -met-ADP also significantly reduced the calcium
response caused by AMP in NT5E co-expressing cells (Fig. 1D,
purple) and marginally inhibited the calcium response caused
by AMP in PAP co-expressing cells (Fig. 1D, green).
Non-hydrolyzable AMP Analog Activates hA1R but Not
hA2BR—We next sought to determine whether ACP, a non-
hydrolyzable analog of AMP (28), could also activate hA1R (Fig.
2, A and B). We found that 1 mM ACP evoked a rapid onset
calcium response in hA1RGqi-expressing cells (Fig. 2C, solid
line) but no response in hA2BR  Gqs-expressing cells (Fig. 2C,
dashed line). ACP, AMP, and adenosine also evoked rapid cal-
cium responses in COS7 cells expressing hA1R  Gqi, but not
Gqi alone, indicating that all of these compounds activate hA1R
when expressed in a different cell line (supplemental Fig. S3).
Adenosine and AMP Are Equipotent hA1R Agonists—Be-
cause our experiments above were performed using a single
concentration of agonist, we next performed dose-response
experiments to determine agonist potency in hA1R  Gqi-ex-
pressing cells (Fig. 3). We found that adenosine stimulated cal-
cium responses with an EC50 of 1.41 M (Table 1), a value con-
sistent with previously published measurements (12, 29).
Interestingly, the EC50 and Emax of AMP in the absence or pres-
ence of -met-ADP (to ensure that AMP was not hydrolyzed
by endogenous NT5E) were not significantly different from
those of adenosine (Fig. 3, Table 1). The non-hydrolyzable ana-
logACPhad an EC50 of 26.1M, 15-fold higher thanAMP. This
reduced potency relative to AMP could reflect the charge dif-
ference between the phosphonate and phosphate groups
(monoanionic versus dianionic at neutral pH, respectively, Fig.
2). The adenosine deamination product inosine had an EC50 of
38.1 M, 27-fold higher than adenosine. The high potency A1R
agonist 2-chloro-N6-cyclopentyladenosine (CCPA) evoked cal-
cium responses with an EC50 of 3.32 nM. The Hill slopes of all
dose responses were near 1.
To test the potency of these compounds in an assay that does
not depend on the use of chimeric G proteins, we utilized a
modified Promega GloSensor assay (Fig. 4, see supplemental
Experimental Procedures for assay details). This assay meas-
ures agonist effects on isoproterenol-evoked cAMP accumula-
tion using a luminescent reporter construct and is conducted in
cells containing only endogenous G proteins. When stimulat-
ing hA1R-expressing cells with adenosine, we observed a
bimodal dose response, with adenosine inhibiting cAMP accu-
mulation at low concentrations and stimulating cAMP accu-
mulation at high concentrations (Fig. 4B). The latter response
was likely due to activation of Gs-coupled A2 receptors, which
HEK293 cells endogenously express (3, 27). Indeed, adenosine
stimulated additional cAMP accumulation in cells transfected
with empty vector (supplemental Fig. S4B). This bimodal
response prevented us from obtaining an EC50 value for
adenosine.
In contrast, CCPA, AMP, ACP, and inosine exclusively
inhibited cAMP accumulation in hA1R-expressing cells (Fig. 4,
FIGURE 1. AMP directly activates hA1R, whereas AMP activates hA2BR indirectly via ectonucleotidase-catalyzed hydrolysis to adenosine. A–D, calcium
mobilization responses in HEK293 cells expressing (A and C) Gqi  hA1R or (B and D) Gqs  hA2BR. Ado, adenosine; N. R., no receptor. C and D, cells were
incubated with the competitive NT5E inhibitor -met-ADP (10 M) for 3 min and then stimulated with 1 mM agonist in the presence of 10 M -met-ADP.
Black, 1 mM AMP in the absence of a transfected adenosine receptor, but in the presence of the respective chimeric G protein. AUC measurements extended
for 1 min from agonist addition. Paired t tests were used to compare AUC data. Black asterisks, statistically significant difference when compared with adenosine
stimulation. Blue asterisks, statistically significant difference when compared with AMP stimulation (in receptor-expressing cells). *, p  0.05, **, p  0.005, ***,
p  0.0005. All data are the average of two experiments performed in duplicate. n  20 –74 cells per condition. All data, including calcium traces, are presented
as means  S.E.
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A and C–F) but had no effects in cells transfected with empty
vector (supplemental Fig. S4, A and C–E). Incubation with 100
ng/ml pertussis toxin for 16 h after transfection abolished the
A1R-mediated inhibition of cAMP accumulation by adenosine,
AMP, and CCPA (data not shown), confirming that signaling
was mediated through endogenous Gi proteins. The rank order
of agonist potency was similar between cAMP accumulation
assays and calciummobilization assays (Table 1). The EC50 val-
ues of AMP were not significantly different in the presence or
absence of 10 M -met-ADP (Fig. 4, C and D), further indi-
cating that AMP stimulates hA1R/Gi-coupled signaling directly
and independent of hydrolysis to adenosine. Moreover, AMP
did not produce a bimodal response like adenosine, arguing
that the signaling effects of AMPwere specific to hA1R and not
due to hydrolysis to adenosine.
ACP Inhibits Forskolin-evoked cAMP Accumulation in
Embryonic Mouse Cortical Neurons—Because the experiments
above relied upon overexpression of adenosine receptors, to
further assess physiological relevance, we next sought to deter-
mine whether the non-hydrolyzable AMP analog (ACP) could
activate native A1R and native downstream signaling compo-
nents in a primary cell type. We selected mouse embryonic
cortical neurons because AMP directly activates mouse A1R
(supplemental Fig. S2),mouseA1R is highly expressed (Fig. 5A),
and A1R activation regulates the physiology of cortical neurons
(24). We utilized a cAMP ELISA assay to measure the second
messenger that is downstream of Gi-coupled mouse A1R. In
addition, we used ACP to ensure that no adenosine was pro-
duced from endogenously expressed ectonucleotidases.
Stimulationof cortical neuronswith the adenylyl cyclase activa-
tor forskolin (10M) for15min increased intracellular cAMPcon-
centrationby10-foldwhencomparedwithbaseline (Fig. 5B,blue).
TheconcentrationofcAMPinneurons treatedwith1mMACPfor
30 min prior to forskolin stimulation was decreased 34.9% when
compared with neurons treated with forskolin alone (Fig. 5B,
green), and cAMP concentration decreased 57.2% in neurons
treated with 1 M N6-cyclopentyladenosine (Fig. 5B, purple), a
high potency A1R agonist. In addition, the potent A1R antagonist
CPX (100 M) completely blocked the effects of ACP and cyclo-
pentyladenosine, as evidencedbynodecrease incAMPconcentra-
tion when compared with forskolin alone (Fig. 5C). Thus, these
data indicate that a non-hydrolyzable AMP analog can directly
activate endogenous signaling pathways downstream of endoge-
nously expressed A1R (i.e. in cells that were not subjected to any
genetic manipulation).
AMP Stimulates hA1R Independent of P2Y Receptors—
HEK293/T cells expressmultiple P2Y receptors (5, 30), andP2Y
FIGURE 2. Non-hydrolyzable AMP analog activates hA1R but not hA2BR. A and B, structures of AMP (A) and the non-hydrolyzable analog ACP (B) at
physiological pH. C, calcium mobilization responses elicited by 1 mM ACP in HEK293 cells expressing (solid line) hA1R  Gqi or (dashed line) hA2BR  Gqs. Cells
expressing Gqi alone did not respond to ACP. AUC measurements extended for 1 min from agonist addition. Paired t tests were used to compare AUC data, ***,
p  0.0005. Data are the average of one (hA2BR) or two (hA1R) experiments performed in duplicate. n  28 –73 cells per condition. All data, including calcium
traces, are presented as means  S.E.
FIGURE 3. Dose-response curves for adenosine, AMP, and related analogs
at hA1R. Calcium mobilization was measured in HEK293 cells expressing
hA1R  Gqi and stimulated with the indicated compounds. For the AMP 
-met-ADP condition, cells were incubated with 10 M -met-ADP for 3
min and then stimulated with AMP in the presence of 10 M -met-ADP.
AUC measurements extended for 1 min from agonist addition. All experi-
ments were performed in duplicate. n  19 – 45 cells per condition. All data
are presented as means  S.E.
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receptors can heterodimerize with A1R, imparting a P2Y-like
pharmacology on A1R (31–33). In addition, P2Y receptors can
be stimulated by AMP analogs but not by AMP (34). Thus, we
evaluated whether AMP-evoked calcium responses in hA1R-
expressing cells could be blockedwith non-selective P2Y antag-
onists (pyridoxalphosphate-6-azophenyl-2,4-disulfonic acid
or suramin). We found that stimulation of untransfected
HEK293 cells with 10MATP elicited a rapid calcium response
(supplemental Fig. S5A, gray). This response was blocked com-
pletely by 100 M pyridoxalphosphate-6-azophenyl-2,4-
disulfonic acid (supplemental Fig. S5A, blue) and by 100 M
suramin (supplemental Fig. S5A, green). However, the same
concentrations of pyridoxalphosphate-6-azophenyl-2,4-dis-
ulfonic acid or suramin did not block calcium responses in
hA1R  Gqi-expressing cells that were stimulated with 10 M
adenosine (supplemental Fig. S5B) or 10 MAMP (supplemen-
tal Fig. S5C). These data thus indicate that AMP signals directly
through hA1R, independent of P2Y receptor activity.
TABLE 1
hA1R dose responses for Ca
2 mobilization assay and GloSensor assay
Agonist
Ca2 mobilization
Inhibition of cAMP accumulation (EC50)EC50 Emaxa
M % M
CCPA 0.00332 104.3  2.0 0.0171
Adenosine 1.41 100
AMP 1.69 94.1  14.1 0.816
AMPb 1.11 99.6  3.3 0.601
ACP 26.1 69.4  3.2 4.95
Inosine 38.1 97.2  3.6 3.22
a Relative to adenosine.
b In the presence of 10 M -met-ADP.
FIGURE 4. Adenosine, AMP, and related analogs inhibit cAMP accumulation in hA1R-expressing cells. A–F, HEK293T cells were co-transfected with a
vector encoding hA1R and GloSensor 22F plasmid and then stimulated with CCPA (A), adenosine (B), AMP (C) or AMP in the presence of 10 M -met-ADP (D),
ACP (E), or inosine (F). Cells were incubated with test compound for 10 min, and then 175 nM ()-isoproterenol was added for 7 min to stimulate cAMP
accumulation. Following incubation, GloSensor cAMP reagent was added, and luminescence was measured. Data were normalized such that 100% inhibition
is equal to the response at the maximal concentration of CCPA and 0% is equal to the response from isoproterenol alone. All experiments were performed in
duplicate. All data are presented as means  S.D.
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His-251 and His-278 in Ligand Binding Pocket Are Required
for AMP toDirectly Activate hA1R—The crystal structures of an
adenosine receptor (hA2AR) co-crystallizedwith adenosine and
an adenosine analog were recently reported (35, 36). From
these structural views of the ligand binding pocket, we selected
two positively charged histidine residues (His-251 andHis-278;
conserved in hA1R) as possibly important for interacting with
the negatively charged phosphate of AMP. We then
mutagenized each of these histidine residues to a non-polar
residue (alanine) to generate hA1R-H251A and hA1R-H278A.
We confirmed that each mutant receptor was expressed and
membrane-localized to the same extent as wild-type hA1R (Fig.
6, A–C).
Next, we measured adenosine and AMP potency at the
mutant receptorswith our calciummobilization assay (Fig. 6D).
We performed these experiments in the presence of 10 M
-met-ADP to prevent AMP from slowly being hydrolyzed to
adenosine. In cells expressing hA1R-H251A  Gqi, adenosine
stimulated calcium mobilization with an EC50 of 1.80 M,
essentially identical to what we observed when stimulating
wild-type hA1Rwith adenosine (Table 1). Likewise,mutation of
His-251 did not affect binding of a radiolabeled agonist to
bovine A1R (37). In contrast, the potency of AMP in hA1R-
H251A  Gqi-expressing cells was drastically reduced, so
much so that we could not obtain a complete dose response. In
cells expressing hA1R-H278A  Gqi, we observed a very weak
response after stimulation with 1 mM adenosine, but no
response at lower concentrations. Furthermore, stimulation
with 1 mM AMP elicited no response. This is also consistent
with a previous study, which showed that mutation of His-278
abolished agonist binding (37). Taken together, our results pro-
vide compelling evidence that adenosine and AMP activate
hA1R directly, with activation requiring an agonist binding
pocket residue (His-278) that is conserved in all adenosine
receptors. Furthermore, the positively charged His-251 residue
is critical for activation of hA1R by a negatively charged nucle-
otide (AMP) but not by adenosine. Importantly, these
mutagenesis experiments conclusively rule out the possibility
that adenosine and AMP stimulate calcium mobilization
through any other receptor in HEK293 cells.
DISCUSSION
Prior to our study, it was unknown whether a receptor for
AMP existed. An older study suggested that AMP might act
FIGURE 5. ACP inhibits cAMP accumulation in mouse embryonic cortical
neurons. Embryonic cortical neurons were dissociated and plated at about
embryonic day 16.5. A, confocal image of cortical neurons immunostained
with an anti-A1R antibody. Scale bar  10 m. B and C, after 1 day in vitro,
neurons were incubated for 30 min with 1 mM ACP or 1 M cyclopentylad-
enosine (CPA) in the absence (B) or presence (C) of 100 M CPX. Neurons were
then stimulated with 10 M forskolin for 15 min, washed, and lysed. Cell
lysates were then applied to a cAMP ELISA assay according to the manufac-
turer’s instructions. cAMP concentrations were normalized to total protein
using a BCA protein assay. Asterisks, statistically significant difference when
compared with forskolin stimulation alone. *, p  0.05, **, p  0.005, ***, p 
0.0005. Data are the average of four ( CPX) or two ( CPX) experiments
performed in duplicate. All data are presented as means  S.E.
FIGURE 6. Expression and activity of hA1R point mutants. A–C, confocal
images of HEK293 cells expressing wild-type hA1R (A), hA1R-H251A (B), or
hA1R-H278A (C) and immunostained with anti-A1R antibodies. Untransfected
HEK293 cells in the same field of view were not immunostained, confirming
antibody specificity. Scale bar  10 m. D, calcium mobilization in HEK293
cells co-expressing the indicated hA1R mutant and Gqi and then stimulated
with increasing concentrations of the indicated compounds. For all condi-
tions, cells were incubated with 10 M -met-ADP for 3 min and then stim-
ulated with agonist in the presence of 10 M -met-ADP. AUC measure-
ments extended for 1 min from agonist addition. All experiments were
performed in duplicate, except H278A-AMP, which was performed in tripli-
cate. n  17– 49 cells per condition. All data are presented as means  S.E.
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directly and indirectly on adenosine receptors (14); however,
the investigators did not fully inhibit themultiple ectonucleoti-
dases that are now known to hydrolyze AMP to adenosine (16,
18, 19). In addition,AMPhas never been evaluated as an agonist
with cloned adenosine receptors, possibly because all previous
assays of adenosine receptor activation required relatively long
incubation periods with agonist, causing uncertainty as to
whether AMP or its hydrolysis product (adenosine) was the
active compound.
Using a novel cell-based assay that allowed for real-time visu-
alization of adenosine receptor activation, we found that AMP
directly activated hA1R, independent of hydrolysis. In support
of this conclusion, we found that AMP activated hA1R in
HEK293 cells as effectively as adenosine, even after inhibition of
the main ectonucleotidase in HEK293 cells. Furthermore, a
non-hydrolyzable analog of AMP also activated hA1R in heter-
ologous cells and in primary neurons, showing that activation
was not due to hydrolysis to adenosine. Our data thus provide
the first direct evidence that hA1R is a receptor for the naturally
occurring nucleotide AMP and argue for reclassification of A1R
as an adenosine and nucleotide (AMP) receptor.
Inbe et al. (3) previously reported that GPR80/GPR99 was a
receptor for adenosine and AMP, although others could not
reproduce this result (4, 5). As suggested by Abbracchio et al.
(4), GPR80/GPR99may have beenmisidentified as a purinergic
receptor because HEK293 cells (the cells used in the GPR80/
GPR99 study and our present study) endogenously express P2Y
receptors in addition to A2AR and A2BR. Alternatively, hetero-
meric interactions between GPR80/GPR99 and endogenous
purinergic receptors could hypothetically impart GPR80/
GPR99 with a novel pharmacological profile.
Neither of these hypothetical possibilities explains whyAMP
activated hA1R in our assays. The HEK293 cells we used do
contain A2 receptors (as evidenced by stimulation of cAMP
production in cells transfected only with GloSensor plasmid
(supplemental Fig. S4)) and P2Y receptors (as evidenced by
ATP-evoked, P2Y antagonist-sensitive calcium responses (sup-
plemental Fig. S5)). However, our data with P2Y antagonists
rule out the possibility that AMP signaled through P2Y recep-
tors. In addition, pointmutations in hA1R shifted or eliminated
responses to AMP, providing strong evidence that AMP sig-
naled directly through hA1R and not through any other recep-
tor in HEK293 cells. AMP also directly stimulated hA1R when
expressed in a different mammalian cell line (COS7 cells (sup-
plemental Fig. S3)).
Our findings were also not an artifact of using a chimeric G
protein to couple hA1R to calcium mobilization. Indeed, we
found that AMP (-met-ADP) and ACP activated hA1R
when coupled to endogenous Gi proteins using the GloSensor
cAMP accumulation assay and that this effect could be blocked
by Gi-specific disruption with pertussis toxin. Our findings
were not an artifact of overexpressing A1R, as ACP inhibited
forskolin-induced cAMP accumulation in mouse cortical neu-
rons that contain only native A1R and downstream signaling
components.
There is a large amount of structure-activity data with
5-substituted adenosine analogs, all of which indicate that A1R
is tolerant of bulky and negatively charged groups at the 5-po-
sition (38–40). This includes 5-ester, 5-carbamoyl, 5-halo-
gen, and 5-sulfide derivatives of adenosine analogs, many of
which are low nanomolar agonists of A1R (41–44). Despite this
extensive literature with unnatural analogs, it is surprising that
the most biologically relevant substitution, a 5-phosphate, has
never, to our knowledge, been directly tested as an A1R agonist.
Our data also revealed that a different adenosine receptor,
hA2BR, is not activated byAMPor the non-hydrolyzable analog
ACP (Fig. S6). Instead, hA2BR was only activated indirectly,
following hydrolysis to adenosine. These results shed light on
seemingly conflicting reports of AMP acting directly as well as
indirectly on adenosine receptors in some tissues but only indi-
rectly via conversion to adenosine in other tissues (6, 12–14, 45,
46). Our data indicate that it is important to determine which
adenosine receptor is activatedwhenAMP is used as the ligand.
If A2BR is activated, the signaling effects of AMP should be
indirect and fully dependent on ectonucleotidases. In contrast,
if A1R is activated, the signaling effects of AMP could be direct
and indirect, with the level of direct activation dependent on
AMP stability and ectonucleotidase levels.
We found that a non-hydrolyzable phosphonate analog of
AMP could activate hA1R. Interestingly, other ectonucleoti-
dase-resistant phosphonate analogs ofAMP reportedly activate
P2X receptors and have cardioprotective activity in vivo (47,
48). Although it was suggested that the cardioprotective effects
of these AMP analogs were due to P2X activation, P2X involve-
ment was never directly tested in vivo with antagonists or
knock-out mice. Given that A1R agonists also have cardiopro-
tective effects (2), it is equally possible that the cardioprotective
effects of these phosphonate analogs, and possibly AMP itself,
are A1R-mediated and not P2X-mediated.
Our findings also have implications forAMP-based prodrugs
that were designed to be full agonists for A2AR only after
hydrolysis by ectonucleotidases (49). Given our results and the
extensive structure-activity data with substitutions at the
5-position, these AMP prodrugs may display a complex phar-
macology with direct A1R activation combined with indirect,
hydrolysis-dependent A2AR activation. Clearly, it will be
important to rigorously evaluate the extent to which these and
other AMP-based prodrugs activate A1R independent of
hydrolysis. This will require pharmacologically or genetically
eliminating all of the AMP hydrolytic enzymes in a given tissue,
a potentially daunting task given that numerous ectonucleoti-
dases are present in complex tissues and are difficult to com-
pletely eliminate experimentally (20).
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